Fibrilación auricular: enfoque para el médico no cardiólogo

  • Julian Eduardo Forero-Gómez Asociación IPS Médicos Internistas de Caldas. http://orcid.org/0000-0002-2424-4857
  • Juliana Milena Moreno Universidad del Bosque
  • Carlos Alberto Agudelo Riesgo de fractura Cayre IPS, Bogotá.
  • Edwin Andrés Rodríguez-Arias Instituto del Corazón de Manizales.
  • Paula Andrea Sánchez-Moscoso ESE Hospital Universitario San Jorge, Pereira.
Palabras clave: Anticoagulación, Arritmias Cardíacas, Fibrilación Auricular

Resumen

La fibrilación auricular es la arritmia más frecuente. Su clasificación según el patrón y tipo clínico permiten decidir el tratamiento a emplear que debe incluir control de síntomas y prevención de cardioembolismo. La elección del tratamiento depende de la presencia de fenómenos desencadenantes de la arritmia, factores de riesgo para tromboembolismo, factores de riesgo para sangrado, función cardiaca, funcionalidad del paciente, costoefectividad de los medicamentos y facilidades para acceder al sistema de salud. El anticoagulante a usar deberá elegirse con base en el tipo de fibrilación auricular y la presencia de contraindicaciones, documentación de anticoagulación inefectiva o alto riesgo de falla al tratamiento con warfarina. En presencia de contraindicaciones para la anticoagulación esta puede emplearse en pacientes con alto riesgo de sangrado cuando los factores de riesgo son controlables o corregibles, pudiéndose ofrecer como alternativa la oclusión de la orejuela auricular en pacientes que persisten con alto riesgo de sangrado.

|Resumen
= 4194 veces | PDF
= 2602 veces| XHTML
= 16 veces|

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Julian Eduardo Forero-Gómez, Asociación IPS Médicos Internistas de Caldas.

Medico Internista, Universidad de Caldas. Médico y Cirujano, Universidad Pontificia Bolivariana. Medico Internista, ESE Hospital Universitario San Jorge, Pereira. Investigador Clínico Asociado, Asociación IPS Médicos Internistas de Caldas. Profesor Ad Honorem, Departamento Clínico, Universidad de Caldas. Profesor catedrático, Facultad de Medicina, Universidad Tecnológica de Pereira Miembro de Número, Asociación Colombiana de Medicina Interna, Capitulo Caldas.

Juliana Milena Moreno, Universidad del Bosque

Medico Residente 2do año de Anestesiología, Universidad del Bosque. Medico General, Instituto del Corazon de Manizales. Medico y Cirujano, Universidad de Caldas

Carlos Alberto Agudelo, Riesgo de fractura Cayre IPS, Bogotá.

Médico General. Riesgo de fractura Cayre IPS, Bogotá DC. Medico, Universidad de Manizales.

Edwin Andrés Rodríguez-Arias, Instituto del Corazón de Manizales.

Medico General, Instituto del Corazón de Manizales. Medico, Universidad de Manizales

Paula Andrea Sánchez-Moscoso, ESE Hospital Universitario San Jorge, Pereira.

Medico General de Apoyo a Medicina Interna, ESE Hospital Universitario San Jorge, Pereira. Medico General Líder en Riesgo Cardiovascular. Saludtotal EPS. Manizales. Medico General, Clínica Versalles, Manizales. Medico y Cirujano, Universidad de Caldas

Citas

(1.) Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170-85. DOI 10.1016/j.cjca.2016.07.591.

(2.) Roselli D, Rodríguez AJ, García AA, Rueda JD. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Colomb Cardiol. 2013 Nov-Dic;20(6):383-5. DOI 10.1016/S0120-5633(13)70089-5.

(3.) Romero M, Chávez D. Carga de enfermedad atribuible a fibrilación auricular en Colombia (2000-2009). Rev Colomb Cardiol. 2014 Nov-Dic;21(6):374-81. DOI 10.1016/j.rccar.2014.08.006.

(4.) Pava-Molano LF, Perafán-Bautista PE. Generalidades de la fibrilación auricular. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):5-8. DOI 10.1016/j.rccar.2016.10.003.

(5.) Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct;37(38):2893-962.

(6.) DePalma SM. Managing atrial fibrillation in primary care. JAAPA. 2016 Jun;29(6):29-33. DOI 10.1097/01.JAA.0000483091.58770.f7.

(7.) Castañeda-Cardona C, Coral-Casas J, Rueda JD, Díaz CE, Rueda MC, Rosselli D. Análisis de costos de atención de infarto cerebral agudo con o sin fibrilación auricular. Acta Neurol Colomb. 2014;30(2):78-82.

(8.) Aristizábal J, Uribe W, Medina E, Velásquez JE, Marín JE, Duque M. Fibrilación auricular: una mirada actual. Rev Colomb Cardiol. 2012;19(5):235-51. DOI 10.1016/S0120-5633(12)70140-7.

(9.) January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec;64(21):e1-76. DOI 10.1016/j.jacc.2014.03.022.

(10.) UK National Clinical Guideline Center. Atrial Fibrillation [Internet]. London: NICE; 2014 [cited 2016 Jun 02]. Available from: https://www.nice.org.uk/guidance/qs93/resources/atrial-fibrillation-2098967360965

(11.) Ocampo-Khon C, Hernández-Ortiz O, Velásquez-Franco J, Tobón-Acosta I, Mejía-Restrepo FA. La clínica de anticoagulación del Hospital Universitario San Vicente de Paúl: demografía, efectividad y complicaciones. Iatreia. 2004 Apr-Jun;17(2):105-14.

(12.) Melgarejo-Rojas E. Prevención farmacológica de embolia por fibrilación auricular y sus escalas de riesgo de embolia y sangrado. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):65-72. DOI 10.1016/j.rccar.2016.10.010.

(13.) Galvez-Olortegui JK, Álvarez-Vargas ML, Galvez-Olortegui TV, Godoy-Palomino A, Camacho-Saavedra L. Current clinical practice guidelines in atrial fibrillation: a review. Medwave. 2016 Jan;16(1):e6365. DOI 10.5867/medwave.2016.01.6365.

(14.) Chinitz JS, Vaishnava P, Narayan RL, Fuster V. Atrial fibrillation through the years: contemporary evaluation and management. Circulation. 2013 Jan;127(3):408-16. DOI 10.1161/CIRCULATIONAHA.112.120758.

(15.) Pinto DA, Sánchez-Vallejo CA, López A, Vergara EP, Sáenz OA, González F, et al. Descripción de los pacientes con fibrilación auricular no valvular que ingresan al servicio de urgencias. Rev Colomb Cardiol. 2016 Jul-Ago;23(4):270-6. DOI 10.1016/j.rccar.2015.09.001.

(16.) Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999 Nov;131(9):688-95.

(17.) Canadian Agency for Drugs and Technologies in Health. Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation [Internet]. Ottaw: CADTH; 2013. [cited 2016 Jan 20]. Available from: http://www.cadth.ca/media/pdf/TR0003_AntithromboticAgents-AF_ScienceReport_e.pdf

(18.) Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016 Aug;388(10046):806-17. DOI 10.1016/S0140-6736(16)31257-0.

(19.) Zhao YJ, Lin L, Zhou HJ, Tan KT, Chew AP, Foo CG, et al. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol. 2016 Oct;220:794-801. DOI 10.1016/j.ijcard.2016.06.087.

(20.) Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep;151(5):297-305.

(21.) Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007 Mar;36(2):151-6.

(22.) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep;365(10):883-91. DOI 10.1056/NEJMoa1009638.

(23.) Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug;370(9586):493-503.

(24.) Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015 Oct;114(4):826-34. DOI 10.1160/TH15-07-0565.

(25.) Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016 Feb;204:88-94.DOI 10.1016/j.ijcard.2015.11.084.

(26.) Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med. 2014 Jun;127(6):519-29.e1. DOI 10.1016/j.amjmed.2013.12.022.

(27.) Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, et al. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin. Clin Drug Investig. 2015 Feb;35(2):109-19. DOI 10.1007/s40261-014-0253-7.

(28.) Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep;365(11):981-92. DOI 10.1056/NEJMoa1107039.

(29.) Giustozzi M, Vedovati MC, Verdecchia P, Pierpaoli L, Verso M, Conti S, et al. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. Eur J Intern Med. 2016 Sep;33:42-6. DOI 10.1016/j.ejim.2016.06.022.

(30.) Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov;369(22):2093-104. DOI 10.1056/NEJMoa1310907.

(31.) García-Peña AA. Evaluación de costo-efectividad de los nuevos anticoagulantes orales en pacientes con fibrilaciónauricular no valvular. Rev Colomb Cardiol. En prensa 2016 Dic. DOI 10.1016/j.rccar.2016.07.012.

(32.) Duque-Ramírez M, Díaz-Martínez JC, Aristizábal-Aristizábal JM, Velásquez-Vélez JE, Marín-Velásquez JE, Uribe-Arango W. Anticoagulantes orales directos para el tratamiento de los pacientes con fibrilación auricular no valvular. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):82-8. DOI 10.1016/j.rccar.2016.10.013.

(33.) Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun;367(9526):1903-12.

(34.) Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of lopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May;360(20):2066-78. DOI 10.1056/NEJMoa0901301.

(35.) Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep;361(12):1139-51. DOI 10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010 Nov;363(19):1877.

(36.) Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul;128(3):237-43. DOI 10.1161/CIRCULATIONAHA.112.001139.

(37.) Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar;364(9):806-17. DOI 10.1056/NEJMoa1007432.

(38.) Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016 Apr;37(14):1145-53. DOI 10.1093/eurheartj/ehv466.

(39.) Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000 Jan;160(1):41-6.

(40.) Berkovits A, Alzman A, Zuñiga P, Pereira J, Mezzano D. Nuevos anticoagulantes orales. Rev Med Chile. 2011;139(10):1347-55. DOI 10.4067/S0034-98872011001000016.

(41.) Arce-Correa JP, Ceballos M, Peña E, Mejía Mejía A, García A, Payares Álvarez K. Análisis de costo-efectividad de dabigatran, rivaroxaban y apixaban comparado con warfarina para prevención de fenómenos tromboembólicos e isquémicos en pacientes adultos con fibrilación auricular no valvular en Colombia [Internet]. Bogotá: Instituto de Evaluación Tecnológica en Salud -IETS y Ministerio de Salud y Protección Social; 2015 [consultado 2016 Dic 12]. Disponible en: http://www.iets.org.co/reportes-iets/Documentacin%20Reportes/Reporte%20EE-181%20Dabigatran%20rivaroxaban%20y%20apixaban%20para%20FA.pdf

(42.) Machado-Alba JE, García-Betancur S, Villegas-Cardona F, Medina-Morales DA. Patrones de prescripción de los nuevos anticoagulantes orales y sus costos económicos en Colombia. Rev Colomb Cardiol. 2016 Jul-Ago;23(4):277-85. DOI 10.1016/j.rccar.2015.08.005.

(43.) Ho MH, Ho CW, Cheung E, Chan PH, Hai JJ, Chan KH, et al. Continuation of dabigatran therapy in “real-world” practice in Hong Kong. PLoS One. 2014 Aug;9(8):e101245. DOI 10.1371/journal.pone.0101245.

(44.) Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015 Apr;350:h1857. DOI 10.1136/bmj.h1857.

(45.) Bouget J, Oger E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thromb Res. 2015 Dec;136(6):1190-4. DOI 10.1016/j.thromres.2015.10.036.

(46.) Ramírez-Barrera JD, Agudelo-Uribe JF, Correa-Velásquez R, González-Rivera E. Fisiopatología de la fibrilación auricular. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):9-14. DOI 10.1016/j.rccar.2016.10.004.

(47.) Martins RP, Galand V, Colette E, Behar N, Pavin D, Leclercq C, et al. Defining nonvalvular atrial fibrillation: A quest for clarification. Am Heart J. 2016 Aug;178:161-7. DOI 10.1016/j.ahj.2016.05.014.

(48.) Di Pasquale G, Zagnoni S, Riva L. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated? Intern Emerg Med. 2015 Feb;10(1):21-4. DOI 10.1007/s11739-014-1181-5.

(49.) Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014 Dec;35(47):3377-85. DOI 10.1093/eurheartj/ehu305.

(50.) Boriani G, Cimaglia P, Fantecchi E, Mantovani V, Ziacchi M, Valzania C, et al. Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):491-6. DOI 10.2459/JCM.0000000000000236.

(51.) Mora-Pabón G. Evaluación de la fibrilación auricular mediante electrocardiograma y Holter. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):27-33. DOI 10.1016/j.rccar.2016.10.006.

(52.) Acevedo CS, Duque-Ramírez M. Papel del ecocardiograma en la evaluación y el tratamiento de pacientes con fibrilación auricular. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):44-51. DOI 10.1016/j.rccar.2016.10.007.

(53.) Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014 Dec;64(21):2222-31. DOI 10.1016/j.jacc.2014.09.028.

(54.) Villegas-García F. Uso de antiarrítmicos en el tratamiento de la fibrilación auricular. Estrategia de control del ritmo. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):112-7. DOI 10.1016/j.rccar.2016.10.018.

(55.) Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016 Aug;388(10046):818-28. DOI 10.1016/S0140-6736(16)31258-2.

(56.) Restrepo-Jaramillo CA. Cardioversión farmacológica. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):52-6. DOI 10.1016/j.rccar.2016.10.008.

(57.) Negrete-Salcedo A, Gil-Roncancio E. Estrategias para el control de la frecuencia cardíaca en pacientes con fibrilación auricular. Rev Colomb Cardiol. 2016;23(Supl 5):108-11. DOI 10.1016/j.rccar.2016.10.017.

(58.) Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013 Feb;47(1):2-10. DOI 10.3109/14017431.2012.740572.

(59.) Al-Khatib SM, Allen Lapointe N, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al . Key Question 1. Rate-Control Drugs. In: Treatment of Atrial Fibrillation. Comparative Effectiveness Review 119. Rockville, MD: Agency for Healthcare Research and Quality; 2013. p. 17-24.

(60.) Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013 May;61(18):1894-903. DOI 10.1016/j.jacc.2013.01.069.

(61.) Anselmino M, Matta M, D’Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1011-8. DOI 10.1161/CIRCEP.114.001938.

(62.) Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015 Apr;372(15):1399-409. DOI 10.1056/NEJMoa1500528.

(63.) Conde D, Costabel JP, Caro M, Ferro A, Lambardi F, Corrales Barboza A, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013 Oct;168(3):2423-5. DOI 10.1016/j.ijcard.2013.02.006.

(64.) Uribe W, Uribe E, Arango L, Sánchez B, Medina LE, Marín JE, et al. Descripción de resultados clínicos con una dosis modificada de amiodarona para la conversión de la fibrilación auricular aguda a ritmo sinusal. Rev Colom Cardiol. 2009 Sep-Oct;16(5):201-13.

(65.) Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1067-75. DOI 10.1586/14779072.2014.943662.

(66.) Yan H, Aung TT, Guoqiang Z, Zhengnan Z, Lan J, Zhiyu Z. Meta-analysis of effect of vernakalant on conversion of atrial fibrillation. BMC Res Notes. 2013 Mar;6:94. DOI 10.1186/1756-0500-6-94.

(67.) Saklani P, Skanes A. Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr Cardiol Rev. 2012 Nov;8(4):302-9.

(68.) Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet. 2016 Aug;388(10046):829-40. DOI 10.1016/S0140-6736(16)31277-6.

(69.) Velasco VM, Rosas F, Betancourt JF, Camargo JM, Santacruz D. ¿Cuándo seleccionar control del ritmo o control de la frecuencia en fibrilación auricular? Rev Colomb Cardiol. 2016 Dic;23(Supl 5):104-7. DOI 10.1016/j.rccar.2016.10.016.

(70.) Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011 Oct;58(17):1795-803. DOI 10.1016/j.jacc.2011.06.055.

(71.) Triana JJ, Castañeda C, Parada L, Otálora-Esteban M, Rosselli D. Costo-efectividad de dabigatrán comparado con warfarina para el tratamiento de pacientes con fibrilación auricular no valvular. Rev Colomb Cardiol. 2016 Mar-Abr;23(2):82-6. DOI 10.1016/j.rccar.2015.06.010.

(72.) Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et al. Systematic review and network metaanalysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014 Jun;4(6):e004301. DOI 10.1136/bmjopen-2013-004301.

(73.) Rodríguez-Reyes H, Arauz-Góngorab A, Asensio-Lafuente E, Celaya-Cotad MJ, Cordero-Cabra A, Guevara-Valdivia M, et al. Reunión multidisciplinaria sobre el uso de los anticoagulantes orales directos en la fibrilación auricular no valvular. Arch Cardiol Mex. 2016. DOI 10.1016/j.acmx.2016.06.006.

(74.) Botero-Arango AF, Duque-Ramírez M, Díaz-Martínez JC, Aristizábal-Aristizábal JM, Velásquez-Vélez JE, Marín-Velásquez JE, et al. Nuevos anticoagulantes orales ¿cuál elegir? Rev Colomb Cardiol. 2016 Dic;23(Supl 5):95-9. DOI 10.1016/j.rccar.2016.10.014.

(75.) Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012 Aug;126(7):860-5. DOI 10.1161/CIRCULATIONAHA.111.060061.

(76.) Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994 Mar;23(4):961-9.

(77.) Senoo K, Lip GY. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial. Int J Cardiol. 2016 Oct;221:379-82. DOI 10.1016/j.ijcard.2016.07.100.

(78.) O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec;36(46):3258-64. DOI 10.1093/eurheartj/ehv476.

(79.) Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2017 Feb;10(1):17-37. DOI 10.1007/s40271-016-0185-9.

(80.) Montenegro-Aldana JJ, Rodríguez-Guerrero DA, Sáenz-Morales LC, López JF. Reversores de los nuevos anticoagulantes. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):100-3. DOI 10.1016/j.rccar.2016.10.015.

(81.) Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug;373(6):511-20. DOI 10.1056/NEJMoa1502000.

(82.) Pollack CV, Eikelboom J, Weitz JI, Reilly PA, Glund S, Dubiel R, et al. Initial results of the RE-VERSE AD trial: Idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery or interventions. Emerg Med J. 2015;32(12):979-80. DOI 10.1136/emermed-2015-205372.9.

(83.) Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 Dec;373(25):2413-24. DOI 10.1056/NEJMoa1510991.

(84.) Roldán V, Cancio S, Gálvez J, Valdés M, Vicente V, Marín F, et al. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective ‘Real-world’ Inception Cohort Study. Am J Med. 2015 Nov;128(11):1237-43. DOI 10.1016/j.amjmed.2015.05.036.

(85.) Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014 Jun;9(4):443-7. DOI 10.1007/s11739-014-1065-8.

(86.) Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015 Jan;175(1):18-24. DOI 10.1001/jamainternmed.2014.5398.

(87.) Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin: The SAMe-TT2R2 Score. Chest. 2013 Nov;144(5):1555-

DOI 10.1378/chest.13-0054.

(88.) Duque-Ramírez M, Díaz-Martínez JC, Marín-Velásquez JE, Velásquez-Vélez JE, Aristizábal-Aristizábal JM, Uribe-Arango W. Uso de anticoagulantes directos en situaciones especiales. Rev Colomb Cardiol. 2016 Dic;23(Supl 5):89-94. DOI 10.1016/j.rccar.2016.11.006.

(89.) Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep;369(13):1206-14. DOI 10.1056/NEJMoa1300615.

(90.) Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar;381(9872):1107-15. DOI 10.1016/S0140-6736(12)62177-1.

(91.) del Portillo H, Badimón JJ, Cabrales JR, Echeverri D. Papel de los nuevos anticoagulantes orales en el tratamiento de la enfermedad coronaria. Rev Colomb Cardiol. 2016 Nov-Dic;23(6):461-3. DOI 10.1016/j.rccar.2016.10.032.

(92.) Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2) CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan;127(2):224-32. DOI 10.1161/CIRCULATIONAHA.112.107128.

(93.) Abraham NS. Management of Antiplatelet Agents and Anticoagulants in Patients with Gastrointestinal Bleeding. Gastrointest Endosc Clin N Am. 2015 Jul;25(3):449-62. DOI 10.1016/j.giec.2015.02.002.

(94.) Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016 Apr;48(4):385-402. DOI 10.1055/s-0042-102652.

(95.) Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015 Dec;66(21):2271-81. DOI 10.1016/j.jacc.2015.09.024.

(96.) Di Minno A, Spadarella G, Spadarella E, Tremoli E, Di Minno G. Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. Thromb Res. 2015 Dec;136(6):1074-81. DOI 10.1016/j.thromres.2015.10.016.

Publicado
2017-10-02
Cómo citar
Forero-Gómez, J. E., Moreno, J. M., Agudelo, C. A., Rodríguez-Arias, E. A., & Sánchez-Moscoso, P. A. (2017). Fibrilación auricular: enfoque para el médico no cardiólogo. Iatreia, 30(4), Pág. 404-422. https://doi.org/10.17533/udea.iatreia.v30n4a05
Sección
Artículos de revisión